Secarna Pharmaceuticals GmbH & Co. KG | WebDisclosure

Basculer en Français

8396	Companies
122097	Keywords
60577	Articles
65553	Press releases

Headlines Articles Press releases Secarna Pharmaceuticals GmbH & Co. KG

Home
Companies
Secarna Pharmaceuticals GmbH & Co. KG

BRIEF

published on 10/31/2024 at 16:08, 1 month 21 days ago

Secarna Pharmaceuticals nomme son nouveau PDG, Konstantin Petropoulos

Nomination Du PDG Produits Biopharmaceutiques Secarna Pharmaceutique Constantin Petropoulos Thérapeutique Par Oligonucléotides
BRIEF

published on 10/31/2024 at 16:08, 1 month 21 days ago

Secarna Pharmaceuticals Appoints New CEO Konstantin Petropoulos

CEO Appointment Biopharmaceuticals Secarna Pharmaceuticals Konstantin Petropoulos Oligonucleotide Therapeutics
PRESS RELEASE

published on 10/31/2024 at 16:03, 1 month 21 days ago

Secarna Announces Appointment of Konstantin Petropoulos as Chief Executive Office
Secarna Pharmaceuticals announces Konstantin Petropoulos as new CEO, succeeding Alexander Gebauer, focusing on oligonucleotide therapeutics. Petropoulos brings extensive industry experience

Business Development CEO Appointment Secarna Pharmaceuticals Konstantin Petropoulos Oligonucleotide Therapeutics
BRIEF

published on 09/09/2024 at 14:05, 3 months 12 days ago

Secarna Pharmaceuticals présentera le potentiel de l'ASO lors du sommet sur les thérapies contre les inflammasomes

Secarna Pharmaceutique Inflammation NLRP3 Les OSA Sommet Sur Les Thérapies À Base D'inflammasome
BRIEF

published on 09/09/2024 at 14:05, 3 months 12 days ago

Secarna Pharmaceuticals to Showcase ASO Potential at Inflammasome Therapeutics Summit

Secarna Pharmaceuticals ASOs Inflammation NLRP3 Inflammasome Therapeutics Summit
PRESS RELEASE

published on 09/09/2024 at 14:00, 3 months 12 days ago

Secarna Pharmaceuticals will present data at 6th Inflammasome Therapeutics Summit demonstrating the potential of ASOs to target the expression of NLRP3
Secarna Pharmaceuticals presents ASO data targeting NLRP3 at Inflammasome Therapeutics Summit, showcasing potential in inflammatory disease treatment

Secarna Pharmaceuticals ASOs NLRP3 Inflammasome Summit Inflammatory Disease
BRIEF

published on 09/04/2024 at 14:05, 3 months 17 days ago

Secarna crée un comité consultatif en oncologie composé des experts Prof. Dr. Eggermont et Prof. Dr. Zippelius

Secarna Pharmaceutique Conseil Consultatif Scientifique SECN-15 Experts En Oncologie Neuropiline 1
BRIEF

published on 09/04/2024 at 14:05, 3 months 17 days ago

Secarna Establishes Oncology Advisory Board with Experts Prof. Dr. Eggermont and Prof. Dr. Zippelius

Scientific Advisory Board Secarna Pharmaceuticals Oncology Experts SECN-15 Neuropilin 1
PRESS RELEASE

published on 09/04/2024 at 14:00, 3 months 17 days ago

Secarna establishes Scientific Advisory Board with leading oncology experts Prof. Dr. Eggermont and Prof. Dr. Zippelius
Secarna Pharmaceuticals GmbH & Co. KG establishes an oncology Scientific Advisory Board with leading experts Prof. Dr. Eggermont and Prof. Dr. Zippelius to guide the development of SECN-15 and the oncology pipeline

Scientific Advisory Board Oncology Therapeutics Secarna Pharmaceuticals SECN-15
BRIEF

published on 07/22/2024 at 14:05, 4 months 30 days ago

Secarna Pharmaceuticals Publishes New Data on LNA-Modified ASOs

Secarna Pharmaceuticals ASOs Immunostimulatory Potential TLR9 Nucleic Acid Therapeutics

Accesswire

Published on 12/21/2024 at 01:30, 17 hours 44 minutes ago

Quantum Biopharma Announces Closing of Second Tranche
Published on 12/21/2024 at 01:30, 17 hours 44 minutes ago

iMetal Resources Closes First Tranche of Previously Announced Non-Brokered Private Placement
Published on 12/21/2024 at 00:05, 19 hours 9 minutes ago

Chloeta Awarded GSA OASIS+ IDIQ Contract for Intelligence, Federal Civilian and Defense Support Services
Published on 12/21/2024 at 00:00, 19 hours 14 minutes ago

Amarc Announces Loan Extension
Published on 12/20/2024 at 23:30, 19 hours 44 minutes ago

Boron One Announces Extension to Early Warrant Exercise Incentive Program

View all ACCESSWIRE

EQS Group

Published on 12/21/2024 at 00:51, 18 hours 23 minutes ago

Acquisition of PSI Transcom GmbH by CHAPTERS platform Altamount Software GmbH
Published on 12/21/2024 at 00:45, 18 hours 29 minutes ago

EQS-Adhoc: PSI sells the Mobility business unit
Published on 12/20/2024 at 19:10, 1 day ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 12/20/2024 at 18:56, 1 day ago

CPI PROPERTY GROUP – Progress on Key Initiatives
Published on 12/20/2024 at 18:00, 1 day 1 hour ago

ARYZTA AG Announces New Board Technology Committee

Les Echos

Published on 12/21/2024 at 12:17, 6 hours 57 minutes ago

AXA annonce la signature d’un accord relatif à la vente d'AXA Investment Managers à BNP Paribas
Published on 12/21/2024 at 12:17, 6 hours 57 minutes ago

AXA announces the signing of a share purchase agreement with BNP Paribas relating to the sale of AXA IM
Published on 12/20/2024 at 18:00, 1 day 1 hour ago

Kapitaalverhoging door uitoefening van inschrijvingsrechten
Published on 12/20/2024 at 18:00, 1 day 1 hour ago

Capital increase through exercise of subscription rights
Published on 12/20/2024 at 17:55, 1 day 1 hour ago

Déclaration des transactions sur actions propres réalisées du 16/12/2024 au 20/12/2024

View all LES ECHOS COMFI WIRE